These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 35084711

  • 21. Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
    Park JS, Park HY, Choi Y.
    Anticancer Res; 2024 Jun; 44(6):2681-2687. PubMed ID: 38821597
    [Abstract] [Full Text] [Related]

  • 22. Metabolic tumor volume derived from 18F-FDG PET/CT as a prognostic parameter for non-small cell lung cancer (NSCLC) patients.
    Ding C, Mao X, Li N, Huang M, Huang Z, Bao W, Li H, Fan J.
    Hell J Nucl Med; 2022 Jun; 25(1):63-70. PubMed ID: 35503557
    [Abstract] [Full Text] [Related]

  • 23. Correlation of epidermal growth factor receptor mutation status and PD-L1 expression with [18F]FDG PET using volume-based parameters in non-small cell lung cancer.
    Ishimura M, Norikane T, Mitamura K, Yamamoto Y, Arai-Okuda H, Murota M, Ibuki E, Kanaji N, Nishiyama Y.
    Nucl Med Commun; 2022 Mar 01; 43(3):304-309. PubMed ID: 34908022
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non-small cell lung cancer.
    Hua J, Li L, Liu L, Liu Q, Liu Y, Chen X.
    Nucl Med Commun; 2021 Nov 01; 42(11):1247-1253. PubMed ID: 34269750
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Evaluation of Amide Proton Transfer-Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters.
    Meng N, Fu F, Feng P, Li Z, Gao H, Wu Y, Zhang J, Wei W, Yuan J, Yang Y, Liu H, Cheng J, Wang M.
    J Magn Reson Imaging; 2022 Oct 01; 56(4):1118-1129. PubMed ID: 35258145
    [Abstract] [Full Text] [Related]

  • 31. Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer.
    Zhang J, Zhao X, Zhao Y, Zhang J, Zhang Z, Wang J, Wang Y, Dai M, Han J.
    Eur J Nucl Med Mol Imaging; 2020 May 01; 47(5):1137-1146. PubMed ID: 31728587
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
    Liu A, Han A, Zhu H, Ma L, Huang Y, Li M, Jin F, Yang Q, Yu J.
    Oncotarget; 2017 May 16; 8(20):33736-33744. PubMed ID: 28422710
    [Abstract] [Full Text] [Related]

  • 34. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 May 16; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 35. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
    Kaira K, Shimizu K, Kitahara S, Yajima T, Atsumi J, Kosaka T, Ohtaki Y, Higuchi T, Oyama T, Asao T, Mogi A.
    Eur J Cancer; 2018 Sep 16; 101():181-190. PubMed ID: 30077123
    [Abstract] [Full Text] [Related]

  • 36. Exploring the correlation between HER2 alterations and 18F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients.
    Ruan M, Chang C, Sun J, Liu L, Wang L, Lei B, Yan H, Zhang H, Xie W, Wang Y.
    J Cancer Res Clin Oncol; 2023 Nov 16; 149(16):14493-14507. PubMed ID: 37572120
    [Abstract] [Full Text] [Related]

  • 37. Correlation between combining 18F-FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer.
    Ruan M, Liu L, Wang L, Lei B, Sun X, Chang C, Shen Y, Xie W.
    Eur J Nucl Med Mol Imaging; 2020 May 16; 47(5):1183-1197. PubMed ID: 31897590
    [Abstract] [Full Text] [Related]

  • 38. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
    Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X.
    Eur J Nucl Med Mol Imaging; 2020 May 16; 47(5):1127-1136. PubMed ID: 31502013
    [Abstract] [Full Text] [Related]

  • 39. Predictive value of 18F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy.
    Akaike K, Saruwatari K, Oda S, Shiraishi S, Takahashi H, Hamada S, Iyama S, Horio Y, Tomita Y, Saeki S, Okamoto S, Ichiyasu H, Fujii K, Sakagami T.
    Int J Clin Oncol; 2020 Apr 16; 25(4):681-690. PubMed ID: 31781994
    [Abstract] [Full Text] [Related]

  • 40. Predictive value of metabolism and its heterogeneity parameters measured by preoperative 18 F-FDG PET/CT for mediastinal occult lymph node metastasis in cN0 lung invasive adenocarcinoma.
    Yang Z, Liu Z, Zhang S, Qiu B, Chai H, Wei L, Li N, He Z, Luo Y, Wei H, Gan M, Xiao G.
    Hell J Nucl Med; 2024 Apr 16; 27(2):78-84. PubMed ID: 39097804
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.